Written by the Core Power Peptides Research Team — biochemists and laboratory specialists compiling and verifying peptide research data. Learn about our quality standards →
Tesamorelin and sermorelin are two of the most frequently compared compounds in growth hormone-releasing hormone (GHRH) research. Both are synthetic analogues of endogenous GHRH, both act at the same pituitary receptor, and both are studied as tools for investigating the growth hormone (GH) axis. Yet they are structurally distinct molecules with different sizes and stability profiles. This guide compares the two at the molecular, mechanistic, and research-application level — strictly for laboratory context.
Tesamorelin and Sermorelin at a Glance
The simplest way to frame the two: sermorelin is a short, minimal GHRH fragment, while tesamorelin is a larger, chemically stabilised GHRH analogue. Both are used in preclinical research as GHRH-receptor agonists, but the modifications built into tesamorelin give it a markedly different stability character. Understanding why comes down to their peptide chains.
What Is Tesamorelin?
Tesamorelin (developmental code TH9507, CAS 218949-48-5) is a fully synthetic 44-residue peptide amide that mirrors the full-length human GHRH(1–44) sequence. Its defining feature is an N-terminal trans-3-hexenoyl group attached to the terminal tyrosine — a modification that distinguishes it as a discrete chemical entity within the GHRH-analogue family. A more detailed molecular breakdown is available on our Tesamorelin 10mg research listing.
What Is Sermorelin?
Sermorelin corresponds to GRF(1–29) — the first 29 amino acids of native GHRH. This truncated fragment is the shortest sequence that retains full GHRH-receptor activity, which is why it has been studied so extensively as a minimal functional analogue. Because it lacks the stabilising modifications engineered into tesamorelin, sermorelin is generally characterised by a shorter functional window in research settings. Core Power Peptides supplies it as Sermorelin Acetate 10mg for laboratory use.
Structural Differences: 44 Residues vs 29
The clearest contrast is chain length. Sermorelin is a 29-amino-acid fragment, while tesamorelin is a 44-residue peptide carrying the molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S and an average molecular weight of approximately 5,135.87 Da. Beyond size, tesamorelin’s N-terminal trans-3-hexenoic acid moiety is the structural element that sets the two apart functionally — sermorelin has no comparable acylation.
Mechanism of Action: A Shared Receptor Target
Both peptides are studied as agonists at the growth hormone-releasing hormone receptor (GHRHR) expressed on anterior-pituitary somatotrophs. In preclinical models, receptor engagement by either compound has been observed to activate the downstream cAMP/PKA signalling cascade and stimulate pulsatile, endogenous GH secretion. Because both target the same receptor, researchers often use them as complementary probes when investigating the hypothalamic-pituitary-somatotropic axis and its native feedback loops.
Stability and Half-Life
This is where the structural gap becomes functionally relevant. The trans-3-hexenoyl modification on tesamorelin has been reported to confer resistance to enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly degrades native GHRH and shorter fragments. Sermorelin, lacking this modification, is comparatively more susceptible to peptidase degradation. For research planning, this difference in stability profile is frequently the deciding factor in which analogue a given assay design favours.
Research Applications
Tesamorelin has been the subject of extensive published investigation, including work examining its effects on adipose tissue and metabolic parameters in controlled studies (see, for example, this pooled analysis of phase 3 trials on PubMed and this study on muscle and fat parameters via PMC). Sermorelin, as the classic minimal GHRH fragment, has a long history as a reference agonist in GH-axis research. In practice, the two are studied side by side precisely because they isolate different variables — chain length and enzymatic stability — against the same receptor target.
Tesamorelin vs Sermorelin: Summary
| Property |
Tesamorelin |
Sermorelin |
| Sequence |
Modified GHRH(1–44) |
GHRH(1–29) fragment |
| Chain length |
44 residues |
29 residues |
| Molecular weight |
~5,135.87 Da |
Smaller (shorter chain) |
| Key modification |
N-terminal trans-3-hexenoyl |
None |
| Receptor target |
GHRHR |
GHRHR |
| Enzymatic stability |
DPP-4 resistant |
Less resistant |
Availability for Research
Both analogues are available from Core Power Peptides for laboratory research: Tesamorelin 10mg and Sermorelin Acetate 10mg, each manufactured to a minimum 99%+ purity, HPLC- and mass-spectrometry-verified, and third-party tested with a certificate of analysis available on request.
This article is provided for informational and research context only. Both compounds are supplied strictly for in vitro and laboratory research use and are not intended for human consumption or therapeutic application. No medical or clinical claims are made.
